Harbin Jixianglong Biotech Co. Issues Nationwide Recall of Semaglutide Over Manufacturing Deviations
Areazine synthesizes this FDA recall directly from FDA's official public data feed. See our methodology for full source attribution and refresh cadence.
Harbin Jixianglong Biotech Co., Ltd. has voluntarily recalled specific lots of Semaglutide used for Rx compounding due to failures in process and bacterial endotoxin validation.
What this FDA recall tells you, and what most readers miss
This notice was issued by FDA on April 2, 2026 and geographically references United States. Its severity classification of "medium" signals how the issuing agency weighs the risk of harm if no action is taken - "critical" and "high" tier alerts typically carry direct consumer actions, while "medium" and "low" tend toward informational guidance or monitoring advisories. The category it belongs to - FDA Recalls - determines the consumer-protection framework behind it, which shapes what remedies (refunds, replacements, repairs, or the recall itself) are available to affected consumers and which agency holds statutory responsibility for enforcement.
Most readers skim a notice like this, check whether they are personally affected, and move on. The more useful lens is to verify its scope, source, and timestamp, then compare related notices without assuming that one record proves a broader trend.
Areazine pairs this record with the original agency URL so you can check the primary source before acting. Its related labels are recall, product-safety, fda, drugs.
What Happened
Harbin Jixianglong Biotech Co., Ltd. has initiated a voluntary recall of Semaglutide drug substance intended for prescription compounding. The recall is the result of Current Good Manufacturing Practice (CGMP) deviations. Specifically, the firm failed to complete necessary process validation and bacterial endotoxin method validation before the product was distributed to the market.
Which Products Are Affected
The recall affects Semaglutide packaged for Rx compounding use only, manufactured by Harbin Jixianglong Biotech Co., Ltd. in Harbin, China. The following configurations are included in the recall:
- 1g: NDC 84385-106-01
- 5g: NDC 84385-106-02
- 10g: NDC 84385-106-06
- 25g: NDC 84385-106-03
- 50g: NDC 84385-106-04
Lot Information:
- Lot Number: CP-030-20250711
- Expiration Date: July 24, 2027
These products were distributed nationwide within the United States.
What You Should Do
Compounding pharmacies and healthcare facilities that have received the affected lot should immediately cease using the product for compounding medications. The recalling firm notified customers of the issue via email on February 13, 2026. For information regarding product returns or further guidance, stakeholders should contact Harbin Jixianglong Biotech Co., Ltd. directly.
Why This Matters
This recall is significant because the failure to validate bacterial endotoxin methods means the safety and purity of the drug substance cannot be guaranteed, potentially exposing patients to contaminated compounded medications.
Source
Information provided by the FDA under Recall Number D-0379-2026.
Original source: FDA Official Notice ↗
Related FDA Recalls
All FDA Recalls →Frequently Asked Questions
Common questions about this FDA recall.